Appili Therapeutics Inc

Research Appili Therapeutics Inc (APLI) on Bullrun: market cap CAD 1.99M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is CAD 1.99M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CAD 206.31K-CAD 2.96M-CAD 11.33Kn/an/aCAD 212.75KCAD 12.46M-CAD 16.38M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24CAD 1.99Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 CAD.

About Appili Therapeutics Inc

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Appili Therapeutics Inc's market cap?

Appili Therapeutics Inc's market capitalization is CAD 1.99M.

What does Appili Therapeutics Inc do?

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections.